Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Join | Sign in
Home>Videos>This Video
  Videos

Return

Preclinical Drug Safety: High Quality Data obtained with a New Automated Patch Clamp Platform
Select Biosciences Ltd

Many compounds have been reported to prolong the QT interval interfering with the hERG channel, leading to life-threatening cardiac arrhythmias. According to FDA guideline every drug going to market must be tested on the hERG channel. Due to this international regulation, there is a great demand for accurate hERG screens as well as for other pacemaker channels. Manual patch clamp is still the gold standard for investigation of ion channels, but throughput is low and a skilled operator is needed. Cytocentrics overcomes these problems by developing the CytoPatch™ Instrument. Thus outsourcing of patch clamp screening offers a true advantage to drug developing companies: Lowering their operating costs and having access to the latest technology and scientific expertise. As examples for the patch clamp quality of the CytoPatch™ Instrument we show that the electrophysiological and pharmacological properties of the cardiac potassium channels like hERG and kv1.5 investigated on the CytoPatch™ Instrument are in excellent agreement with data known from manual patch clamp: This demonstrates that ion channel screening on the CytoPatch™ Instrument delivers the same high data quality known from manual patch clamp at a throughput level required for safety pharmacology screening.

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial
Liberia-U.S. partnership planning Phase 3 trial and study of Ebola survivors.
NIH Works to Improve Kidney Health for All
Statement of NIDDK Director Griffin P. Rodgers, M.D., for World Kidney Day 2015.
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study
Phase 1 study to evaluate the novel oncology immunotherapeutic MOR209/ES414 for prostate cancer.
NIH-supported Clinical Trials to Evaluate Long-acting, Injectable Antiretroviral Drugs
Both trials are expected to be completed in 2017.
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
Paramedics May be First Line of Treatment for Stroke
NIH study demonstrates feasibility of getting drugs to stroke patients faster.
Cancer Treatment with KU Origins Enters Second Clinical Trial
Cleave Biosciences has begun a Phase 1 clinical trial to evaluate CB-5083.
Ebola Vaccine Trial Opens in Liberia
Study led by Liberia-NIH partnership will test two experimental vaccines.
NIH Launches Tool to Advance Down Syndrome Research
Web portal will help approved professionals to plan clinical studies.
NIH Researchers Tackle Thorny Side of Gene Therapy
Pre-clinical studies in mice reveal ways to reduce cancer risk with modified treatment.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters